Production of Antibody Fragments in a Bioreactor
Clinical use of antibodies or antibody fragments is dependent on highly effective production systems. Antibody fragments like single-chain Fv or Fab have been successfully expressed in microorganisms for more than a decade, and the most commonly used host has been Escherichia coli . The ease of genetic manipulation in E. coli has made it the first choice for expression of antibody fragments, and by fusion of the protein to a signal sequence, antibody fragments are secreted to the periplasm of the bacteria, allowing correct folding and recovery of functionally active proteins. Finally, E. coli can be grown to high cell densities in an inexpensive medium allowing high volumetric yield of antibody fragments.
- Gene Therapy of Glioblastoma Multiforme with a Bicistronic Retroviral Vector Expressing Human IL-2 and HSV-tK
- T-Cell Receptor Clonotype Mapping Using Denaturing Gradient Gel Electrophoresis: Analysis of Clonal T-Cell Responses in Melanoma
- Clinical Application of Tissue and Serum Markers in Breast Cancer
- Genome-Wide Methylation Analysis
- Dissecting the Urokinase Activation Pathway Using Urokinase-Activated Anthrax Toxin
- The APC Tumor Suppressor Pathway
- Purification of the Mitotic Checkpoint Complex, an Inhibitor of the APC/C From HeLa Cells
- Cellular Predictive Factors of Drug Resistance in Non-Small Cell Lung Carcinomas
- Mitogen-Activated Protein Kinase Signaling in Drug-Resistant Neuroblastoma Cells
- Quantitative Analysis of PRAME for Detection of Minimal Residual Disease in Leukemia